Drug
Rezpegaldesleukin clinical trials
Also written NKTR-358 and LY3471851.
Keep track of what changes. Save the rezpegaldesleukin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 1
Nektar Therapeutics (13) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)
Studies
Open first, then newest update. How each study uses rezpegaldesleukin is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisRecruitingPhase 3Nektar TherapeuticsNCT07690371Written as Rezpegaldesleukin
- Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes MellitusRecruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT07142252Written as Rezpegaldesleukin
- A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisRecruitingPhase 3Nektar TherapeuticsNCT07711418Written as Rezpegaldesleukin
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)CompletedPhase 2Nektar TherapeuticsNCT06340360Written as Rezpegaldesleukin
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic DermatitisActive, not recruitingPhase 2Nektar TherapeuticsNCT06136741Written as Rezpegaldesleukin
- A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)CompletedPhase 2Nektar TherapeuticsNCT04433585Written as LY3471851
- A Study of LY3471851 in Participants With PsoriasisCompletedPhase 1Nektar TherapeuticsNCT04119557Written as LY3471851
- A Study of LY3471851 in Participants With EczemaCompletedPhase 1Nektar TherapeuticsNCT04081350Written as LY3471851
- A Phase I Study of LY3471851 in Healthy ParticipantsCompletedPhase 1Nektar TherapeuticsNCT05565729Written as LY3471851
- A Study of LY3471851 in Healthy ParticipantsCompletedPhase 1Nektar TherapeuticsNCT04133116Written as LY3471851
- A Study of NKTR-358 (LY3471851) in Healthy ParticipantsCompletedPhase 1Nektar TherapeuticsNCT04380324Written as LY3471851
- A Single-Dose Study of LY3471851 in Healthy ParticipantsCompletedPhase 1Nektar TherapeuticsNCT04998487Written as LY3471851
- A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)CompletedPhase 1Nektar TherapeuticsNCT03556007Written as LY3471851
- A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)TerminatedPhase 2Nektar TherapeuticsNCT04677179Written as LY3471851
Codes
What other systems call rezpegaldesleukin · ClinicalTrials.gg INT018244
- UNII (FDA) VGR86P26ERREZPEGALDESLEUKINOne source FDA
- NCI Thesaurus C188643RezpegaldesleukinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VGR86P26ER | REZPEGALDESLEUKIN | One source FDA |
| NCI Thesaurus | C188643 | Rezpegaldesleukin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.